MedPath

Assessment of the Glycemic Responses to Nutritional Products

Not Applicable
Completed
Conditions
Glycemic Response
Registration Number
NCT05179031
Lead Sponsor
Nutricia Research
Brief Summary

This study assesses the glycemic responses to nutritional products. During a study visit fasted subjects will consume one serving of the reference product or the test product. Capillary blood samples will be taken at baseline and at several time-points over a 2-hr period. Several nutritional products will be tested over time.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
13
Inclusion Criteria
  • Age ≥ 18 and ≤ 65 years
  • Body mass index (BMI) between 18.5 and 27 kg/m²
Exclusion Criteria
  • Known history of gastrointestinal disease, bariatric surgery, AIDS, hepatitis, a history or presence of clinically important endocrine (including Type 1 or Type 2 diabetes mellitus), or any condition which might, in the opinion of the medical director either: 1) make participation dangerous to the subject or to others, or 2)affect the results.
  • Use of medications known to influence carbohydrate metabolism, gastrointestinal function or appetite, including, but not limited to adrenergic blockers, diuretics, thiazolidinediones, metformin and systemic corticosteroids within 4 weeks of the screening visit, or any medication which might, in the opinion of the medical director either: 1) make participation dangerous to the subject or to others, or 2) affect the results.
  • Major trauma or surgical event within 3 months of screening.
  • Known intolerance, sensitivity or allergy to test products.
  • Extreme dietary habits, as judged by the Investigator (i.e. Atkins diet, very high protein diets, etc.).
  • History of cancer in the prior two years, except for non-melanoma skin cancer.

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Primary Outcome Measures
NameTimeMethod
The glycemic index of nutritional products9 test days (test days will be separated by at least 1 day in between tests for each participant)
Secondary Outcome Measures
NameTimeMethod
The postprandial glucose levels at each time point after each test product compared with the mean of the 3 references9 test days (test days will be separated by at least 1 day in between tests for each participant)
The postprandial incremental area under the curve (iAUC) after each test product compared with the mean of the 3 references9 test days (test days will be separated by at least 1 day in between tests for each participant)

Trial Locations

Locations (1)

INQUIS Clinical Research, Ltd

🇨🇦

Toronto, Ontario, Canada

INQUIS Clinical Research, Ltd
🇨🇦Toronto, Ontario, Canada

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.